Organizing Committee
OCM Member
St George’s University of London, Institute of Cancer Vaccines and Immunotherapy , United Kingdom
Biography :

Angus Dalgleish qualified in medicine from University College London and trained in internal medicine and medical oncology in Brisbane and Sydney. He did his MD with Professor Robin Weiss at the ICR before becoming a Senior Clinical Fellow at the MRC Clinical Research Centre. Since 1992 he has been Professor of Oncology at St. George’s. He has over 370 publications and has co-authored 5 books and been an editorial member of many oncology and immunology journals.

Research Interest :


OCM Member
Research Advisor and Leader
Elanco Global Headquarters , USA
Biography :

Arvind graduated in Veterinary Medicine with specialization in Veterinary Microbiology (MVSc) from India. Following early years in mixed Veterinary practice, he served as Assistant Professor Veterinary Microbiology in the Vet School Palampur HP, India. He started his career in infection and immunity research with Masters in Immunology from Imperial College School of Medicine, London and PhD in Veterinary Microbiology from University of Edinburgh (UK) in 2005. He was hired by Lohmann Animal Health GmbH as Director Research based in Hannover, Germany from 2012-15. After merger with Elanco Animal Health, he served as Director Research Poultry Vaccines (EU) based in Germany. In 2016, He moved to the US in the Global Vaccine Research team, as Leader Bacteriology - Vaccine Research Centre Elanco Animal Health, based in Indianapolis. Currently, he is serving as Research Advisor and Leader – Discovery Biology Research (Bacteriology & Parasitology) ERL, Global Research and External Innovation, at the Elanco Global Headquarters in Indiana.

Research Interest :

Global Lead on Vaccine & Biologics Research

OCM Member
Vaccine and Immunotherapy Center , USA
Biography :

Dr. Poznansky is an innovator whose work bridges academic discovery and clinical care. As a leader in the field of leukocyte migration and the modulation of leukocyte trafficking and function, he has linked discovery with the generation of new vaccine and immunotherapeutic approaches in infectious diseases, cancer and type 1 diabetes. Dr. Poznansky has gained recognition for establishing a new model for translational research that accelerates the process by which basic biological discoveries move towards products and technologies that improve patient care and treatment. Since 2009 he has served as the director of the translational Vaccine and Immunotherapy Center (VIC) at MGH, which is putting this model into practice. The goal of VIC is to enable efficient and rapid transition of promising technologies through preclinical development and into the clinical stage of development through technology spin outs, partnerships or out-licensing. He oversees the research work of a team of investigators, postdoctoral fellows and other trainees addressing key research questions regarding these new therapeutics and vaccines, and leads an operational team that facilitates the execution of business, regulatory, manufacturing, and other developmental tasks associated with the preclinical translation of these candidates. Relevant to this presentation, Dr. Poznansky is the PI of a DTRA funded study to develop a novel vaccine for Q fever and directs a program at VIC which has developed three new immunotherapeutic approaches to the treatment of cancer including ovarian cancer and mesothelioma. His team leaders, including Dr. Jeff Gelfand and Dr. Satoshi Kashiwagi, direct the development of a program to develop a novel, safe and efficacious near infra-red light based adjuvant for both infectious disease and cancer vaccines. Dr. Poznansky obtained his B.Sc. and his MD at the University of Edinburgh and his PhD in Medical Sciences at Cambridge University. He also served as a Resident in Clinical Immunology at the Addenbrooke’s Hospital in Cambridge, UK and a Captain in the Royal Army Medical Corps (V). He completed his post-doctoral research training in retrovirology at Harvard Medical School and the Dana Farber Cancer Institute. He completed his infectious diseases fellowship training at Imperial College and Harvard Medical School. He is the scientific founder of three biotech companies and serves as the Co-Director of the Medicine Innovation Program at MGH.

Research Interest :

He has linked discovery with the generation of new vaccine and immunotherapeutic approaches in infectious diseases, cancer and type 1 diabetes.

OCM Member
Professor of Biochemistry, Faculty of Pharmacy, Cairo University , Egypt
Biography :

She had her Bachelor of Veterinary Medical science Cairo University 1992, MSc of Virology Cairo University 1999 and PhD in Virology Cairo University2004. She promoted to Associate professor in 2009 then to Professor of Virology and Immunology 2014 at the National Research Centre (NRC). She has a special interest in Molecular Virology; currently she is working on several viruses which cause great economic losses such as FMD, BVD, ND, IB, ILT and reemerging viral diseases such as Bluetongue. In addition, she has several researches on diagnosis and control of these viruses. She has been principle investigator for many projects funded by NRC and STDF. She has supervised many MSc and PhD thesis and a chief Editor in many national and international Journals; she is also a member of many national and international specified associations. She is a member of the Biosafety and Biorisk committee and CEO of the Virology Unit in the Department of Microbiology at the NRC.

Research Interest :

He has linked discovery with the generation of new vaccine and immunotherapeutic approaches in infectious diseases, cancer and type 1 diabetes.

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
General Query
More details about

Terms and Conditions


Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.


Registration fees do not include insurance of any kind.


Please notes that any (or) all transportation and parking is the responsibility of the registrant.


Press permission must be obtained from Allied Academies Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied academies are a non-profit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter:

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact to request a personalized letter of invitation.

Regarding refunds, all bank charges will be for the registrant's account.

Cancellation, Postponement, and Transfer of Registration

All cancellations or modifications of registration must be made in writing to Program Manager (

Cancellation Policy

If Allied academies cancel this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Conferences (AAC) event which must occur within one year from the date of cancellation.


If Allied academies postpone an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies Conferences event which must occur within one year from the date of postponement.

Transfer of Registration

All fully paid registrations are transferable to other persons from the same organization if registered person is unable to attend the event. Transfers must be made by the registered person in writing to Program ManagerDetails must be included with the full name of replacement person, their title, contact phone number, and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of the conferences.

However, Registration cannot be transferred if it is intimated within 14 days of the respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 60 days of the conference: Eligible for Full Refund less $100 Service Fee
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

Authorization Policy

Copyright © 2019-2020 Allied Academies, All Rights Reserved.